Comparative study of antiplatelet drugs in vitro: Distinct effects of cAMP-elevating drugs and GPIIb/IIIa antagonists on thrombin-induced platelet responses

Thrombosis Research

Volumn 95, Issue 1, 1999, Pages 19-29

  Matsumoto, Yutaka ^a   Marukawa, Keiko ^a   Okumura, Hiromi ^a   Adachi, Tomoya ^a   Tani, Takeshi ^a   Kimura, Yukio ^a  

^a Thromb and Vasc Res Laboratory   (Japan)

Author keywords

cAMP; GP IIb IIIa; Platelet function; Thrombin

Indexed keywords

ABCIXIMAB; ANTITHROMBOCYTIC AGENT; CALCIUM; CILOSTAZOL; N,N DIMETHYLFORMAMIDE; PROSTAGLANDIN E1; THROMBIN; THROMBIN RECEPTOR ACTIVATING PEPTIDE; THROMBOCYTE FACTOR 4; THROMBOXANE A2; TIROFIBAN;

ARTICLE; CALCIUM CELL LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; HUMAN TISSUE; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE RELEASE REACTION;

ALPROSTADIL; ANTIBODIES, MONOCLONAL; BLOOD PLATELETS; CELLS, CULTURED; CYCLIC AMP; DRUG EVALUATION, PRECLINICAL; HEMOSTATICS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; TETRAZOLES; THROMBIN; TYROSINE;

EID: 0033165938     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(98)00189-3     Document Type: Article

References (40)

1. Marcus A.J., Safier L.B. Thromboregulation. Multicellular modulation of platelet reactivity in hemostasis and thrombosis FASEB J. 7:1993;516-522.
2. Fitzgerald D.J. Platelet activation in the pathogenesis of unstable angina. Importance in determining the response to plasminogen activators Am J Cardiol. 68:1991;51B-57B.
3. Harrison P., Cramer E.M. Platelet α-granules. Blood Reviews. 7:1993;52-62.
4. Ross R. The pathogenesis of atherosclerosis. A perspective for the 1990s Nature. 362:1993;801-809.
5. Zwaal R.F.A., Schroit A.J. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood. 89:1997;1121-1132.
6. Antiplatelet trialists' collaboration Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients BMJ. 308:1994;81-106.
7. Coller B.S., Anderson K., Weisman H.F. New antiplatelet agents. Platelet GPIIb/IIIa antagonists Thromb Haemost. 74:1995;302-308.
8. The EPIC Investigators Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 330:1994;956-961.
9. Topol E.J., Califf R.M., Weisman H.F., Ellis S.G., Tcheng J.E., Worley S., Ivanhoe R., George B.S., Fintel D., Weston M., Sigmon K., Anderson K.M., Lee K.L., Willerson J.T. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis. Results at six months Lancet. 343:1994;881-886.
10. Mills D.C., Smith J.B. The influence on platelet aggregation of drugs that affect the accumulation of adenosine 3′:5′-cyclic monophosphate in platelets. Biochem J. 121:1971;185-196.
11. Liu M., Simon M.I. Regulation by cAMP-dependent protein kinase of a G-protein-mediated phospholipase C. Nature. 382:1996;83-87.
12. Kimura Y., Tani T., Kanbe T., Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneim-Forsch. 35:1985;1144-1149.
13. Peerlinck K., Lepeleire I.D., Goldberg M., Farrell D., Barrett J., Hand E., Panebianco D., Deckmyn H., Vermylen J., Arnout J. MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man. Circulation. 88:1993;1512-1517.
14. 2+ indicators with greatly improved fluorescence properties. J Biol Chem. 260:1985;3440-3450.
15. Cobbold P.H., Rink T.J. Fluorescence and bioluminescence measurement of cytoplasmic free calcium. Biochem J. 248:1987;313-328.
16. Vu T.H., Hung D.T., Wheaton V.I., Coughlin S.R. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 64:1991;1057-1068.
17. Hung D.T., Vu T.H., Wheaton V.I., Ishii K., Coughlin S.R. Cloned platelet thrombin receptor is necessary for thrombin-induced platelet activation. J Clin Invest. 89:1992;1350-1353.
18. Sargeant P., Sage S.O. Calcium signaling in platelets and other nonexcitable cells. Pharmac Ther. 64:1994;395-443.
19. Nishikawa M., de Lanerolle P., Lincoln T.M., Adelstein R.S. Phosphorylation of mammalian myosin light chain kinases by the catalytic subunit of cyclic AMP-dependent protein kinase and by cyclic GMP-dependent protein kinase. J Biol Chem. 259:1984;8429-8436.
20. Siess W., Lapetina E.G. Functional relationship between cyclic AMP-dependent protein phosphorylation and platelet inhibition. Biochem J. 271:1990;815-819.
21. Lerea K.M., Glomset J.A., Krebs E.G. Agents that elevate cAMP levels in platelets decrease thrombin binding. J Biol Chem. 262:1987;282-288.
22. Nishikawa M., Komada F., Morita K., Deguchi K., Shirakawa S. Inhibition of platelet aggregation by the cAMP-phosphodiesterase inhibitor, cilostamide, may not be associated with activation of cAMP-dependent protein kinase. Cell Signal. 4:1992;453-463.
23. Connolly A.J., Ishihara H., Kahn M.L., Farese R.V. Jr., Coughlin S.R. Role of the thrombin receptor in development and evidence for a second receptor. Nature. 381:1996;516-519.
24. Ishihara H., Connolly A.J., Zeng D., Kahn M.L., Zheng Y.M., Timmons C., Tram T., Coughlin S.R. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature. 386:1997;502-506.
25. Kleiman N.S., Raizner A.E., Jordan R., Wang A.L., Norton D., Mace K.F., Joshi A., Coller B.S., Weisman H.F. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab. Implications for inhibition of the internal pool of GPIIb/IIIa receptors JACC. 26:1995;1665-1671.
26. Musial J., Niewiarowski S., Rucinski B., Stewart G.J., Cook J.J., Williams J.A., Edmunds L.J. Inhibition of platelet adhesion to surfaces of extracorporeal circuits by disintegrins. RGD-containing peptides from viper venoms Circulation. 82:1990;261-273.
27. Bernabei A., Gikakis N., Kawalska M.A., Niewiarowski S., Edmunds L.H. Iloprost and echistatin protect platelets during simulated extracorporeal circulation. Ann Thorac Surg. 59:1995;149-153.
28. Hiramatsu Y., Gikakis N., Gorman J.H., Khan M.M.H., Hack C.E., Velthuis H.T.E., Sun L., Marcinkiewicz C., Rao A.K., Niewiarowski S., Colman R.W., Edmunds L.H., Anderson H.L. A baboon model for hematologic studies of cardiopulmonary bypass. J Lab Clin Med. 130:1997;412-420.
29. Hiramatsu Y., Gikakis N., Anderson H.L., Gorman J.H., Marcinkiewicz C., Gould R.J., Niewiarowski S., Edmunds L.H. Tirofiban provides "platelet anesthesia" during cardiopulmonary bypass in baboons. J Thorac Cardiovas Surg. 113:1997;182-193.
30. Gemmell C.H., Sefton M.V., Yeo E.L. Platelet-derived microparticle formation involves glycoprotein IIb-IIIa. J Biol Chem. 268:1993;14586-14589.
31. Fox J.E.B., Reynolds C.C., Austin C.D. The role of calpain in stimulus-response coupling. Evidence that calpain mediates agonist-induced expression of procoagulant activity in platelets Blood. 76:1990;2510-2519.
32. Fox J.E.B., Austin C.D., Reynolds C.C., Steffen P.K. Evidence that agonist-induced activation of calpain causes the shedding of procoagulant-containing microvesicles from the membrane of aggregating platelets. J Biol Chem. 266:1991;13289-13295.
33. Fox J.E.B., Taylor R.G., Taffarel M., Boyles J.K., Goll D.E. Evidence that activation of platelet calpain is induced as a consequence of binding of adhesive ligand to the integrin, glycoprotein IIb-IIIa. J Cell Biol. 120:1993;1501-1507.
34. Rendu F., Lavie P., Saleun S., Lasne D. Platelet procoagulant activity is independent of aggregation. Nouv Rev Fr Hematol. 37:1995;327-331.
35. Weiss H.J., Lages B. Platelet prothrombinase activity and intracellular calcium responses in patients with storage pool deficiency, glycoprotein IIb-IIIa deficiency, or impaired platelet coagulant activity - A comparison with Scott syndrome. Blood. 89:1997;1599-1611.
36. Moliterno D.J., Califf R.M., Aguirre F.V., Anderson K., Sigmon K.N., Weisman H.F., Topol EJ for the EPIC study investigators Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Am J Cardiol. 75:1995;559-562.
37. Hanson S.R., Harker L.A. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin PPACK. Proc Natl Acad Sci USA. 85:1988;3184-3188.
38. Eidt J.F., Allison P., Noble S., Ashton J., Golino P., McNatt J., Buja L.M., Willerson J.T. Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury. J Clin Invest. 84:1989;18-27.
39. Kereiakes D.J., Kleiman N.S., Ambrose J., Cohen M., Rodriguez S., Palabrica T., Herrmann H.C., Sutton J.M., Weaver W.D., Mckee D.B., Fitzpatrick V., Sax F.L. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. JACC. 27:1996;536-542.
40. Theroux P., Kouz S., Roy L., Knudtson M.L., Diodati J.G., Marquis J.F., Nasmith J., Fung A.Y., Boudreault J.R., Delage F., Dupuis R., Kells C., Bokslag M., Steiner B., Rapold H.J. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. Circulation. 94:1996;899-905.